Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.37B 10.84B 10B 9.24B 17.51B 1,180B 17.8B 119B 46.84B 581B 46.46B 45.45B 2,001B P/E 2026 *
-75.9x
P/E 2027 * 54.2x
Enterprise Value 11.84B 10.38B 9.57B 8.84B 16.76B 1,130B 17.04B 114B 44.83B 556B 44.47B 43.5B 1,915B EV / Sales 2026 *
7.92x
EV / Sales 2027 * 5.11x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 week+2.48%
Current month-0.45%
1 month+14.01%
3 months+5.37%
6 months+6.43%
Current year-5.69%
1 week 456
Extreme 456
492
1 month 403.7
Extreme 403.7
492
3 years 113.8
Extreme 113.8
519.6
5 years 48.4
Extreme 48.4
519.6
10 years 5.91
Extreme 5.906
519.6
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Change 5-day change 1-year change 3-year change Capi.($)
-4.24%+2.48%+77.50%+134.03% 12.37B
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.67%-0.28%+56.63%+147.05% 26.8B
Weighted average by Cap. -0.91%-1.46%+56.14%+137.59%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.21B 1.12B 2.12B 143B 2.15B 14.43B 5.66B 70.25B 5.61B 5.49B 242B 2.21B 1.93B 1.78B 1.65B 3.12B 210B 3.17B 21.29B 8.35B 104B 8.28B 8.1B 357B
Net income -201M -176M -162M -150M -284M -19.17B -289M -1.94B -761M -9.44B -755M -738M -32.5B 308M 270M 249M 230M 435M 29.34B 443M 2.97B 1.16B 14.45B 1.16B 1.13B 49.74B
Net Debt -529M -464M -427M -395M -749M -50.47B -761M -5.11B -2B -24.86B -1.99B -1.94B -85.56B -1.09B -959M -884M -817M -1.55B -104B -1.58B -10.56B -4.14B -51.43B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
-
Date Price Change
26-07-10 €467.00 -4.24%
26-07-09 €487.70 -0.29%
26-07-08 €489.10 +2.77%
26-07-07 €475.90 +3.39%
26-07-06 €460.30 +1.01%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
536.70USD
Average target price
678.71USD
Spread / Average Target
+26.46%

Quarterly revenue - Rate of surprise